Page 92 - GPD-4-3

Gene & Protein in Disease Dopaminergic dysfunction as pre-addiction

13. Blum K, Braverman ER, Holder JM, et al. The reward clinical pilot trial. Mol Neurobiol. 2021;58:3335-3346.
deficiency syndrome: A biogenetic model for the diagnosis
and treatment of impulsive, addictive and compulsive doi: 10.1007/s12035-021-02312-1
behaviors. J Psychoact Drugs. 2000;32:1-112. 24. Blum K, Siwicki D, Baron D, Modestino EJ, Badgaiyan RD.
The benefits of genetic addiction risk score (GARS™) and pro-
doi: 10.1080/02791072.2000.10736099
dopamine regulation in combating suicide in the American
14. Wenzel A. The Sage Encyclopedia of Abnormal and Clinical Indian population. J Syst Integr Neurosci. 2018;4:10.15761/
Psychology. Vol. 1. United States: Sage Publications; 2017. JSIN.1000195.
15. Kótyuk E, Urbán R, Hende B, et al. Development and doi: 10.15761/JSIN.1000195
validation of the reward deficiency syndrome questionnaire
(RDSQ-29). J Psychopharmacol. 2022;36:409-422. 25. Blum K, Steinberg B, Gondre-Lewis MC, et al. A Review
of DNA risk alleles to determine epigenetic repair of
doi: 10.1177/02698811211069102 mRNA expression to prove therapeutic effectiveness in
16. Blum K, Han D, Gupta A, et al. Statistical validation of risk reward deficiency syndrome (RDS): Embracing “precision
alleles in genetic addiction risk severity (GARS) test: Early behavioral management”. Psychol Res Behav Manag.
identification of risk for alcohol use disorder (AUD) in 2021;14:2115-2134.
74,566 case-control subjects. J Pers Med. 2022;12:1385. doi: 10.2147/PRBM.S292958
doi: 10.3390/jpm12091385 26. Vereczkei A, Barta C, Magi A, et al. FOXN3 and GDNF
17. Blum K, Lott L, Ponce JV, et al. In search of reward deficiency polymorphisms as common genetic factors of substance use
syndrome (RDS)-free controls: The “holy grail” in genetic and addictive behaviors. J Pers Med. 2022;12:690.
addiction risk testing. Curr Psychopharmacol. 2020;9:7-21. doi: 10.3390/jpm12050690
18. Blum K, Baron D, Lott L, et al. Biotechnical development of 27. Thanos PK, Hanna C, Mihalkovic A, et al. Genetic correlates
genetic addiction risk score (GARS) and selective evidence as a predictor of bariatric surgery outcomes after 1 year.
for inclusion of polymorphic allelic risk in substance use Biomedicines. 2023;11:2644.
disorder (SUD). J Syst Integr Neurosci. 2020;6:10.15761/
JSIN.1000221. doi: 10.3390/biomedicines11102644
doi: 10.15761/JSIN.1000221 28. Fried L, Modestino EJ, Siwicki D, et al. Hypodopaminergia
and “precision behavioral management”(PBM): It is
19. Blum K, Chen AL, Thanos PK, et al. Genetic addiction a generational family affair. Curr Pharm Biotechnol.
risk score (GARS)™, a predictor of vulnerability to opioid
dependence. Front Biosci. 2018;10:175-196. 2020;21:528-541.
doi: 10.2174/1389201021666191210112108
doi: 10.2741/e816
20. Blum K, Brodie MS, Pandey SC, et al. Researching mitigation 29. Brewer R, Blum K, Bowirrat A, et al., Transmodulation
of alcohol binge drinking in polydrug abuse: KCNK13 of dopaminergic signaling to mitigate hypodopminergia
and RASGRF2 gene (s) risk polymorphisms coupled with and pharmaceutical opioid-induced hyperalgesia. Curr
genetic addiction risk severity (GARS) guiding precision Psychopharmacol. 2020;9:164-184.
pro-dopamine regulation. J Pers Med. 2022;12:1009. doi: 10.2174/2211556009999200628093231
doi: 10.3390/jpm12061009 30. Blum K, Oscar-Berman M, Demetrovics Z, Barh D, Gold MS.
21. Gupta A, Bowirrat A, Gomez LL, et al. Hypothesizing in the Genetic addiction risk score (GARS): Molecular neurogenetic
face of the opioid crisis coupling Genetic Addiction Risk evidence for predisposition to reward deficiency syndrome
Severity (GARS) testing with electrotherapeutic nonopioid (RDS). Mol Neurobiol. 2014;50:765-796.
modalities such as H-Wave could attenuate both pain and doi: 10.1007/s12035-014-8726-5
hedonic addictive behaviors. Int J Environ Res Public Health.
2022;19:552. 31. Blum K, Bowirrat A, Lewis MC, et al. Exploration of
epigenetic state hyperdopaminergia (Surfeit) and genetic
doi: 10.3390/ijerph19010552 trait hypodopaminergia (Deficit) during adolescent brain
22. Blum K, Modestino EJ, Gondre-Lewis M, et al. The benefits development. Curr Psychopharmacol. 2021;10:181-196.
of genetic addiction risk score (GARS™) testing in substance doi: 10.2174/2211556010666210215155509
use disorder (SUD). Int J Genom Data Min. 2018;2018:115.
32. Thanos PK, Hanna C, Mihalkovic A, et al. The First
doi: 10.29014/IJGD-115.000015 exploratory personalized medicine approach to improve
23. Moran M, Blum K, Ponce JV, et al. High genetic addiction bariatric surgery outcomes utilizing psychosocial and
risk score (GARS) in chronically prescribed severe chronic genetic risk assessments: Encouraging clinical research.
opioid probands attending multi-pain clinics: An open J Pers Med. 2023;13:1164.

Volume 4 Issue 3 (2025) 10 doi: 10.36922/gpd.8090